Skip to main content
OpenTrials

Clinical trial condition

Richter's Transformation

Explore clinical trials studying Richter's Transformation. Study availability and eligibility vary by location and protocol.

7 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Richter's Transformation trial results

Recruiting

CD45BE-HSPC + CART-45 Cells

NCT07451054

Conditions
B-Cell Non-Hodgkin Lymphoma (NHL), Hemic and Lymphatic Diseases, Hodgkin Disease, +13 more
Locations
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details
Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731

Conditions
B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +36 more
Locations
  • The First Affiliated Hospital of Bengbu Medical University Bengbu, Anhui, China
  • Anhui Provincial Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Chao Yang Hospital,Capital Medical University Beijing, Beijing Municipality, China
View all 29 locations
View Trial Details
Recruiting

ONO-4538 Study in Patients With Richter's Transformation

NCT06936943

Conditions
Richter's Transformation
Locations
  • Aichi Cancer Center Nagoya, Aichi-ken, Japan
  • Kyusyu University Hospital Fukuoka, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital Hiroshima, Japan
  • Hokkaido University Hospital Sapporo, Hokkaido, Japan
View Trial Details
Recruiting

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

NCT06043674

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Winship Cancer Institute at Emory University Atlanta, Georgia, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States
View Trial Details
Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details

Related conditions